Tumor immunity against adult T-cell leukemia

Mari Kannagi, Nanae Harashima, Kiyoshi Kurihara, Takashi Ohashi, Atae Utsunomiya, Ryuji Tanosaki, Masato Masuda, Masao Tomonaga, Jun Okamura

Research output: Contribution to journalReview articlepeer-review

32 Citations (Scopus)


Human T-cell leukemia virus type-I (HTLV-I) causes adult T-cell leukemia (ATL) in a small population of infected individuals after a long incubation period. Although the process of clonal evolution of ATL cells may involve multiple steps, ATL cells from half of the ATL cases still retain the ability to express HTLV-I Tax, a key molecule of HTLV-I leukemogenesis. A recent finding of reactivation of Tax-specific cytotoxic T lymphocytes (CTL) in ATL patients after hematopoietic stem cell transplantation suggests the presence of Tax expression in vivo and potential contribution of the CTL to antitumor immunity. This is consistent with the results of a series of animal experiments indicating that Tax-specific CTL limit the growth of HTLV-I-infected cells in vivo, although the animal model mimics only an early phase of HTLV-I infection and leukemogenesis. Establishment of an insufficient HTLV-I-specific T-cell response and an increased viral load in orally HTLV-I-infected rats suggests that host HTLV-I-specific T-cell response at a primary HTLV-I infection can be a critical determinant of persistent HTLV-I levels thereafter. These findings indicate that Tax-targeted vaccines may be effective for prophylaxis of ATL in a high-risk group, and also for therapy of ATL in at least half the cases.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalCancer science
Issue number5
Publication statusPublished - 2005 May
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tumor immunity against adult T-cell leukemia'. Together they form a unique fingerprint.

Cite this